The Week in Review: February 16 – February 23, 2018

Friday, February 23, 2018 News Recap: Way to Go, Ontario! Ontario removes fibrosis requirement for HCV treatment effective Feb 28th.  Action Hepatitis Canada has just shared some great news: Ontario has announced today that effective February 28, 2018, the fibrosis requirement for hepatitis C treatment will be removed! Finally, diagnosis of chronic hepatitis C and genotyping is all that will be required in Ontario to access treatment. This announcem...

Marijuana might save your liver, according to a new study

Weed has been shown to have various health benefits: pain management, quelling nausea, and, of course, the calming effects of relaxation. And now that legal weed for recreational use is becoming increasingly common (9 states and Washington, D.C., full list here), an increasing number of studies are being funded to better illustrate and understand marijuana’s effects on your health. The latest study? Smoking weed just might be incredibly beneficial for

The Week in Review: January 26 – February 2, 2018

Friday, February 2, 2018 News Recap: From the Uh-Oh Department: HCV Can Reactivate with Treatment of Non-hepatic Cancer. Hepatitis C virus (HCV) reactivation occurred in approximately 1 out of 5 patients treated for non-hepatic cancer, posing renewed risk for hepatic injury and possibly complicating the cancer treatment. Compensation Update: Compensation – New Update for 86-90 Late Claims. If you or a family member received a blood transfusion o...

Viral suppression protects against long-term liver damage caused by older HIV drugs

Most people living with HIV now have a normal life expectancy as a consequence of effective antiretroviral treatment, and viral suppression with modern therapies has been shown to have a beneficial effect on liver health. Liver disease remains a leading cause of serious illness and death in people with HIV. Much of this can be attributed to co-infection with HCV and/or hepatitis B virus (HBV), or problematic alcohol use. It is well known that older, and n

The Week in Review: September 22 – September 29, 2017

Friday, September 29, 2017 News Recap: Merck discontinues HCV programs. There were rumours, but now it’s official: Merck has announced that it will discontinue the development of the investigational combination regimens MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir) for the treatment of chronic hepatitis C virus (HCV) infection. In a statement the company said the decision was made based on a review of available Pha...

Three or more cups of coffee daily halves mortality risk in patients with both HIV and HCV

Patients infected by both human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at specific risk of end-stage liver disease and greater risk of cardiovascular diseases and cancer. In addition, HIV infection accelerates the progression of chronic hepatitis C to fibrosis and development of cirrhosis and end-stage liver disease. In these HIV-HCV co-infected patients, drinking at least three cups of coffee each day halved the risk of all-cause mor